North Shore University Hospital
North Shore University Hospital was paid $87.68M by Medicaid between Jan 2018 and Dec 2024, across 428 billing codes. Its largest line is A0427, emergency ambulance ride, advanced life support — 5.0% of everything it billed.
MANHASSET, NY 11030
Next to other Ambulance providers in New York
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,262 | $1.03M | |
| 2019 | 70,539 | $5.43M | |
| 2020 | 168,244 | $13.10M | |
| 2021 | 242,791 | $18.08M | |
| 2022 | 255,648 | $17.12M | |
| 2023 | 256,885 | $18.43M | |
| 2024incomplete | 200,918 | $14.49M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 5.0% | 33,081 | 29,266 | $4.34M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.5% | 23,116 | 22,200 | $3.92M |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 4.4% | 36,569 | 32,497 | $3.86M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.9% | 12,377 | 12,200 | $3.41M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.4% | 21,072 | 20,388 | $2.95M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.1% | 21,979 | 18,118 | $2.72M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 3.0% | 5,077 | 4,997 | $2.63M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.0% | 13,665 | 13,339 | $2.59M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.6% | 12,888 | 12,508 | $2.24M |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 2.4% | 1,131 | 1,121 | $2.11M |
| C1889 | Implantable/insertable device, not otherwise classified | 2.4% | 20,938 | 3,729 | $2.11M |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 2.2% | 16,453 | 16,255 | $1.96M |
416 more codes
| 78815 | Positron emission tomography (PET) for limited area imaging | 2.1% | 1,710 | $1.87M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.9% | 21,265 | $1.67M |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 1.7% | 4,118 | $1.53M |
| G0378 | Hospital observation service, per hour | 1.7% | 2,335 | $1.49M |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 1.7% | 3,865 | $1.46M |
| 76641 | 1.6% | 12,047 | $1.38M | |
| 19083 | 1.5% | 1,093 | $1.30M | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 1.4% | 3,530 | $1.27M |
| 72197 | 1.4% | 2,673 | $1.25M | |
| 93975 | 1.4% | 2,927 | $1.19M | |
| 74183 | 1.3% | 2,463 | $1.12M | |
| A9585 | Injection, gadobutrol, 0.1 ml | 1.2% | 12,735 | $1.06M |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 1.1% | 6,777 | $928K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.0% | 5,893 | $899K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.0% | 1,123 | $888K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 5,038 | $873K |
| 52000 | <1% | 941 | $867K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 12,248 | $837K |
| 72141 | <1% | 2,260 | $767K | |
| 76830 | Ultrasound, transvaginal | <1% | 6,449 | $765K |
| 71250 | <1% | 5,074 | $712K | |
| 80053 | Comprehensive metabolic panel | <1% | 39,524 | $675K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 2,052 | $670K |
| 77049 | <1% | 1,387 | $670K | |
| 73221 | <1% | 2,011 | $642K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,127 | $629K |
| 76536 | <1% | 5,475 | $604K | |
| A0434 | Specialty care transport (sct) | <1% | 2,334 | $597K |
| A0425 | Ground mileage, per statute mile | <1% | 72,599 | $587K |
| 74178 | <1% | 1,489 | $576K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,045 | $576K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,948 | $562K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,355 | $538K |
| 93454 | <1% | 304 | $505K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,006 | $467K |
| 93970 | <1% | 1,754 | $462K | |
| A4648 | Tissue marker, implantable, any type, each | <1% | 1,769 | $447K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 16,444 | $440K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,038 | $439K |
| 77066 | Tomosynthesis, mammo | <1% | 3,041 | $413K |
| C1769 | Guide wire | <1% | 3,012 | $404K |
| 76770 | <1% | 2,493 | $391K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,142 | $367K |
| 77065 | Tomosynthesis, mammo | <1% | 3,710 | $361K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 1,868 | $360K |
| 75574 | <1% | 1,442 | $360K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,923 | $358K |
| 95806 | <1% | 600 | $356K | |
| 86850 | <1% | 13,956 | $355K | |
| 93458 | <1% | 177 | $345K | |
| 70491 | <1% | 1,681 | $342K | |
| 76642 | <1% | 4,128 | $341K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 11,375 | $282K |
| 95782 | <1% | 285 | $272K | |
| 70486 | <1% | 1,911 | $270K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,201 | $269K |
| 59025 | Fetal non-stress test | <1% | 1,466 | $263K |
| 76775 | <1% | 3,560 | $246K | |
| 77080 | <1% | 3,409 | $234K | |
| 10005 | <1% | 635 | $232K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 1,776 | $231K |
| 86901 | <1% | 13,619 | $228K | |
| 70498 | <1% | 1,243 | $220K | |
| 62323 | <1% | 473 | $213K | |
| 86900 | <1% | 14,120 | $209K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 302 | $206K |
| 70544 | <1% | 841 | $200K | |
| 93971 | <1% | 1,770 | $196K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 521 | $196K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,763 | $196K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,026 | $183K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 9,642 | $177K |
| D0120 | Dental checkup, returning patient | <1% | 3,438 | $175K |
| 73700 | <1% | 1,109 | $171K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 4,564 | $170K |
| 77085 | <1% | 785 | $165K | |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 2,598 | $162K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,237 | $161K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,974 | $160K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 8,702 | $155K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 6,292 | $154K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 2,344 | $153K |
| 71271 | <1% | 1,385 | $152K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 947 | $150K |
| 86923 | <1% | 1,171 | $146K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 25,820 | $143K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 986 | $142K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,043 | $141K |
| 51700 | <1% | 516 | $141K | |
| 72146 | <1% | 467 | $138K | |
| 70496 | <1% | 1,372 | $136K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 807 | $128K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 105 | $122K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 941 | $117K |
| 86922 | <1% | 1,138 | $114K | |
| 76000 | <1% | 1,560 | $109K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 6,308 | $107K |
| 95800 | <1% | 561 | $106K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,718 | $106K |
| 82803 | <1% | 7,570 | $104K | |
| 76942 | <1% | 792 | $96K | |
| 86480 | <1% | 1,640 | $96K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,112 | $95K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,406 | $95K |
| 95811 | <1% | 131 | $93K | |
| 78816 | <1% | 92 | $91K | |
| J3490 | Unclassified drugs | <1% | 14,039 | $85K |
| D1110 | Prophylaxis - adult | <1% | 1,636 | $84K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,904 | $83K |
| 93356 | <1% | 351 | $79K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,510 | $78K |
| C9399 | Unclassified drugs or biologicals | <1% | 1,793 | $75K |
| 86902 | <1% | 144 | $74K | |
| 76870 | <1% | 865 | $73K | |
| 74174 | <1% | 231 | $72K | |
| C8937 | Computer-aided detection, including computer algorithm analysis of breast mri image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure) | <1% | 1,144 | $72K |
| 72156 | <1% | 200 | $69K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,962 | $67K |
| 73130 | <1% | 1,933 | $64K | |
| 87536 | <1% | 1,429 | $63K | |
| 97161 | <1% | 807 | $63K | |
| 90715 | <1% | 2,299 | $62K | |
| 51797 | <1% | 237 | $62K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,339 | $61K |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 250 | $60K |
| 72100 | <1% | 1,684 | $59K | |
| 73718 | <1% | 169 | $57K | |
| 88185 | <1% | 239 | $57K | |
| 73030 | <1% | 1,940 | $55K | |
| 72110 | <1% | 1,018 | $55K | |
| 87641 | <1% | 1,907 | $49K | |
| 73630 | <1% | 2,062 | $48K | |
| 83880 | <1% | 2,664 | $47K | |
| D0140 | Limited oral evaluation - problem focused | <1% | 1,320 | $46K |
| 72157 | <1% | 115 | $46K | |
| 86360 | <1% | 1,218 | $46K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,801 | $46K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 318 | $44K |
| 73562 | <1% | 1,603 | $43K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 174 | $42K |
| 93880 | <1% | 170 | $42K | |
| 76882 | <1% | 1,070 | $41K | |
| 88321 | <1% | 269 | $41K | |
| 72158 | <1% | 113 | $40K | |
| 75561 | <1% | 49 | $39K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 3,881 | $38K |
| 77072 | <1% | 1,160 | $38K | |
| 88271 | <1% | 179 | $38K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 472 | $38K |
| 0225U | <1% | 3,467 | $38K | |
| 76377 | <1% | 1,286 | $38K | |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | <1% | 551 | $37K |
| 93017 | <1% | 616 | $37K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,915 | $37K |
| 93308 | <1% | 287 | $35K | |
| 85027 | <1% | 23,518 | $34K | |
| 78306 | <1% | 146 | $34K | |
| 80061 | Lipid panel | <1% | 3,553 | $33K |
| 72131 | <1% | 309 | $33K | |
| 88307 | <1% | 546 | $33K | |
| 70480 | <1% | 191 | $33K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 11,043 | $33K |
| 70543 | <1% | 77 | $32K | |
| 74018 | <1% | 1,060 | $32K | |
| 76376 | <1% | 905 | $32K | |
| 64483 | <1% | 56 | $31K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 261 | $31K |
| 83020 | <1% | 1,326 | $31K | |
| 73110 | <1% | 1,103 | $31K | |
| J2704 | Injection, propofol, 10 mg | <1% | 7,824 | $30K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 17,164 | $30K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 14 | $29K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,267 | $29K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,037 | $29K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,636 | $28K |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 192 | $28K |
| 73610 | <1% | 1,472 | $28K | |
| 88237 | <1% | 155 | $27K | |
| 85610 | <1% | 10,043 | $27K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 309 | $27K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 39 | $26K |
| 88304 | <1% | 1,118 | $26K | |
| 19281 | <1% | 25 | $26K | |
| 76937 | <1% | 221 | $25K | |
| 76818 | <1% | 300 | $25K | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,640 | $24K |
| 90651 | <1% | 92 | $24K | |
| 96376 | <1% | 1,768 | $24K | |
| 73564 | <1% | 793 | $24K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 829 | $22K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,383 | $22K |
| 86359 | <1% | 1,169 | $22K | |
| 72040 | <1% | 649 | $22K | |
| 19081 | <1% | 13 | $21K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 104 | $20K |
| 88173 | <1% | 716 | $20K | |
| 99386 | <1% | 156 | $20K | |
| 36000 | <1% | 886 | $20K | |
| 90688 | <1% | 1,063 | $19K | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 53 | $19K |
| 73502 | <1% | 708 | $19K | |
| 87800 | <1% | 928 | $19K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 980 | $18K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 741 | $18K |
| 87653 | <1% | 578 | $17K | |
| 81025 | <1% | 6,670 | $17K | |
| 86769 | <1% | 784 | $17K | |
| 88275 | <1% | 175 | $17K | |
| 82565 | <1% | 2,498 | $16K | |
| 88172 | <1% | 323 | $15K | |
| 86780 | <1% | 3,774 | $15K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,159 | $15K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 84 | $14K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 117 | $14K |
| 36224 | <1% | 27 | $14K | |
| 76498 | <1% | 318 | $14K | |
| 84702 | <1% | 7,612 | $14K | |
| D0274 | Bitewings - four radiographic images | <1% | 369 | $13K |
| 51784 | <1% | 170 | $13K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,877 | $13K |
| C1874 | Stent, coated/covered, with delivery system | <1% | 12 | $13K |
| 99385 | <1% | 105 | $13K | |
| 81003 | <1% | 9,441 | $12K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,491 | $12K |
| 72070 | <1% | 298 | $11K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 22,541 | $11K |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 123 | $11K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,092 | $11K |
| 74160 | <1% | 63 | $11K | |
| 12001 | <1% | 27 | $11K | |
| 86703 | <1% | 1,083 | $10K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,094 | $10K |
| 20611 | <1% | 15 | $10K | |
| 55700 | <1% | 12 | $10K | |
| 78830 | <1% | 27 | $9K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,789 | $9K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,541 | $9K |
| 87631 | <1% | 251 | $9K | |
| 86803 | <1% | 1,778 | $9K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 41 | $9K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,983 | $9K |
| 49083 | <1% | 18 | $9K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 14 | $9K |
| 86353 | <1% | 199 | $9K | |
| A0433 | Advanced life support, level 2 (als 2) | <1% | 59 | $9K |
| C9600 | Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch | <1% | 12 | $9K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 50 | $8K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 52 | $8K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,100 | $8K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,938 | $8K |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 180 | $8K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 25 | $8K |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 638 | $8K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,755 | $8K |
| 81513 | <1% | 133 | $7K | |
| A9561 | Technetium tc-99m oxidronate, diagnostic, per study dose, up to 30 millicuries | <1% | 134 | $7K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,878 | $7K |
| D0220 | Intraoral - periapical first radiographic image | <1% | 484 | $7K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 156 | $7K |
| 83690 | <1% | 7,903 | $7K | |
| 82330 | <1% | 6,281 | $7K | |
| 90732 | <1% | 127 | $7K | |
| 88184 | <1% | 202 | $6K | |
| 77001 | <1% | 28 | $6K | |
| 83655 | <1% | 482 | $6K | |
| 82962 | <1% | 6,640 | $6K | |
| 99205 | Prolong outpt/office vis | <1% | 39 | $6K |
| 88312 | <1% | 193 | $6K | |
| 87340 | <1% | 1,814 | $6K | |
| 90656 | <1% | 374 | $6K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,848 | $6K |
| 72195 | <1% | 12 | $6K | |
| D0330 | Panoramic radiographic image | <1% | 157 | $6K |
| 73120 | <1% | 120 | $5K | |
| 12011 | <1% | 13 | $5K | |
| 87481 | <1% | 133 | $5K | |
| 85730 | <1% | 8,125 | $5K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,244 | $5K |
| 86762 | <1% | 577 | $5K | |
| Q3014 | Telehealth originating site facility fee | <1% | 209 | $5K |
| 88341 | <1% | 179 | $5K | |
| 86765 | <1% | 618 | $5K | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 67 | $5K |
| 87640 | <1% | 1,800 | $5K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,781 | $5K |
| 86481 | <1% | 116 | $5K | |
| 73590 | <1% | 367 | $5K | |
| 81001 | <1% | 11,760 | $4K | |
| 76801 | <1% | 53 | $4K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 333 | $4K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,431 | $4K |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,182 | $4K |
| C1758 | Catheter, ureteral | <1% | 89 | $4K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 163 | $3K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 38 | $3K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,311 | $3K |
| 90686 | <1% | 160 | $3K | |
| 88360 | <1% | 53 | $3K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 399 | $3K |
| 82677 | <1% | 277 | $3K | |
| 83615 | <1% | 1,160 | $3K | |
| 88342 | <1% | 107 | $3K | |
| 83605 | <1% | 6,946 | $3K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 954 | $3K |
| 84484 | <1% | 7,252 | $3K | |
| 76881 | <1% | 30 | $3K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 212 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,126 | $3K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 25 | $3K |
| 58300 | <1% | 15 | $3K | |
| 86880 | <1% | 220 | $2K | |
| 73080 | <1% | 120 | $2K | |
| 86870 | <1% | 99 | $2K | |
| 87581 | <1% | 195 | $2K | |
| 87486 | <1% | 195 | $2K | |
| 73560 | <1% | 88 | $2K | |
| 83735 | <1% | 5,698 | $2K | |
| 81002 | <1% | 1,527 | $2K | |
| 82947 | <1% | 6,801 | $2K | |
| 84295 | <1% | 6,798 | $2K | |
| 90682 | <1% | 41 | $2K | |
| 82435 | <1% | 6,788 | $2K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 15 | $2K |
| 82950 | <1% | 717 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 13 | $2K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 26 | $2K |
| 88313 | <1% | 38 | $2K | |
| 87186 | <1% | 1,502 | $2K | |
| 82105 | <1% | 344 | $2K | |
| 73200 | <1% | 12 | $2K | |
| 84550 | <1% | 605 | $2K | |
| 82570 | <1% | 618 | $2K | |
| 86336 | <1% | 389 | $2K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 14 | $2K |
| 88300 | <1% | 246 | $1K | |
| 84704 | <1% | 213 | $1K | |
| 84156 | <1% | 706 | $1K | |
| 82607 | <1% | 247 | $1K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 14 | $1K |
| 72050 | <1% | 25 | $1K | |
| 90649 | <1% | 15 | $1K | |
| 87077 | <1% | 888 | $1K | |
| 82728 | <1% | 322 | $1K | |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 13 | $1K |
| 84439 | <1% | 308 | $1K | |
| 72082 | <1% | 14 | $1K | |
| 87205 | <1% | 858 | $1K | |
| 99152 | <1% | 529 | $1K | |
| 86140 | <1% | 1,392 | $1K | |
| 84100 | <1% | 2,611 | $1K | |
| 97165 | <1% | 12 | $971.11 | |
| D0210 | Intraoral - complete series of radiographic images | <1% | 50 | $969.10 |
| 73090 | <1% | 89 | $771.01 | |
| 85379 | <1% | 1,897 | $762.64 | |
| 81329 | <1% | 13 | $739.80 | |
| 87070 | <1% | 671 | $738.05 | |
| 81243 | <1% | 27 | $729.38 | |
| 73521 | <1% | 30 | $709.23 | |
| 97802 | <1% | 66 | $675.35 | |
| 86706 | <1% | 118 | $664.60 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 731 | $662.16 |
| 87040 | <1% | 1,581 | $626.43 | |
| 73620 | <1% | 41 | $615.36 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 553 | $610.69 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 468 | $497.65 |
| 84132 | <1% | 6,962 | $455.80 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 28 | $445.43 |
| 85652 | <1% | 1,173 | $437.20 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 214 | $430.52 |
| 73522 | <1% | 15 | $413.40 | |
| 82550 | <1% | 1,020 | $386.46 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 363 | $347.59 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 66 | $313.41 |
| 95117 | <1% | 20 | $286.44 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 97 | $277.37 |
| 73140 | <1% | 27 | $253.79 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 124 | $250.45 |
| 93321 | <1% | 20 | $234.08 | |
| 85384 | <1% | 60 | $231.58 | |
| 84145 | <1% | 257 | $230.60 | |
| 85014 | <1% | 6,871 | $228.44 | |
| 72170 | <1% | 51 | $222.26 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 37 | $188.44 |
| 71100 | <1% | 12 | $181.82 | |
| 74019 | <1% | 26 | $176.17 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 102 | $162.52 |
| 82746 | <1% | 29 | $154.90 | |
| 82043 | <1% | 28 | $112.99 | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 20 | $98.20 |
| 83550 | <1% | 77 | $98.14 | |
| 85018 | <1% | 5,908 | $89.35 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 43 | $87.93 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 90 | $84.14 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 12 | $80.16 |
| 80076 | <1% | 14 | $65.20 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 13 | $63.50 |
| 87081 | <1% | 111 | $59.97 | |
| 84157 | <1% | 70 | $55.99 | |
| 83540 | <1% | 44 | $55.33 | |
| 82945 | <1% | 69 | $55.01 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 111 | $45.79 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 26 | $45.13 |
| 89051 | <1% | 111 | $36.70 | |
| A0888 | Noncovered ambulance mileage, per mile (e.g., for miles traveled beyond closest appropriate facility) | <1% | 715 | $36.22 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 12 | $32.46 |
| 84480 | <1% | 24 | $25.64 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 59 | $25.33 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 15 | $22.01 |
| 82365 | <1% | 26 | $21.61 | |
| 86592 | <1% | 14 | $19.62 | |
| 84436 | <1% | 38 | $11.40 | |
| 82553 | 0% | 12 | $0.00 | |
| 87625 | 0% | 27 | $0.00 | |
| 99429 | 0% | 55 | $0.00 | |
| 99080 | 0% | 1,956 | $0.00 | |
| 82010 | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.